TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07049159: Safety, and Efficacy Study of ShigETEC, a Live, Attenuated, Oral Combination Vaccine to Prevent Shigella and ETEC Disease Delivered to Healthy Adults Ages 18 to 50 Years Old

Sponsor: Eveliqure Biotechnologies GmbH · Phase: PHASE2 · Area: INFECTIOUS_VACCINE · Target Enrollment: 72 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$9,408,000

Rescue Site Savings

+$6,203,400

Unlock Full NCT07049159 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07049159 Rescue Dossier →